15,410 Shares in Lantheus Holdings Inc (LNTH) Acquired by Dupont Capital Management Corp

Dupont Capital Management Corp bought a new stake in Lantheus Holdings Inc (NASDAQ:LNTH) in the 1st quarter, HoldingsChannel.com reports. The institutional investor bought 15,410 shares of the medical equipment provider’s stock, valued at approximately $377,000.

A number of other institutional investors have also recently bought and sold shares of the business. PNC Financial Services Group Inc. raised its position in Lantheus by 51.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 1,694 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 575 shares during the last quarter. Thrivent Financial for Lutherans raised its position in shares of Lantheus by 2.2% during the fourth quarter. Thrivent Financial for Lutherans now owns 26,714 shares of the medical equipment provider’s stock worth $418,000 after acquiring an additional 587 shares during the last quarter. Martingale Asset Management L P raised its position in shares of Lantheus by 0.7% during the fourth quarter. Martingale Asset Management L P now owns 91,678 shares of the medical equipment provider’s stock worth $1,435,000 after acquiring an additional 599 shares during the last quarter. Victory Capital Management Inc. raised its position in shares of Lantheus by 4.0% during the fourth quarter. Victory Capital Management Inc. now owns 16,426 shares of the medical equipment provider’s stock worth $257,000 after acquiring an additional 639 shares during the last quarter. Finally, Legal & General Group Plc raised its position in shares of Lantheus by 0.9% during the fourth quarter. Legal & General Group Plc now owns 82,403 shares of the medical equipment provider’s stock worth $1,272,000 after acquiring an additional 721 shares during the last quarter. Hedge funds and other institutional investors own 93.79% of the company’s stock.

In related news, Director A Frederick Robertson sold 3,932 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $22.77, for a total transaction of $89,531.64. Following the completion of the sale, the director now owns 43,062 shares of the company’s stock, valued at $980,521.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Brian A. Markison sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 8th. The stock was sold at an average price of $25.22, for a total value of $126,100.00. Following the sale, the director now directly owns 72,467 shares of the company’s stock, valued at approximately $1,827,617.74. The disclosure for this sale can be found here. Insiders have sold 115,102 shares of company stock valued at $2,818,648 in the last ninety days. 2.60% of the stock is currently owned by insiders.

A number of equities analysts have recently issued reports on LNTH shares. Zacks Investment Research downgraded Lantheus from a “buy” rating to a “hold” rating in a research report on Wednesday, March 20th. ValuEngine upgraded Lantheus from a “hold” rating to a “buy” rating in a research report on Wednesday, February 20th. Finally, BidaskClub upgraded Lantheus from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 22nd. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $23.33.

Shares of LNTH opened at $25.50 on Monday. Lantheus Holdings Inc has a 1 year low of $12.59 and a 1 year high of $26.40. The company has a quick ratio of 3.82, a current ratio of 4.57 and a debt-to-equity ratio of 3.16. The stock has a market cap of $961.19 million, a PE ratio of 27.13, a P/E/G ratio of 1.78 and a beta of 1.52.

Lantheus (NASDAQ:LNTH) last released its earnings results on Tuesday, April 30th. The medical equipment provider reported $0.28 EPS for the quarter, topping the consensus estimate of $0.25 by $0.03. Lantheus had a return on equity of 59.57% and a net margin of 12.17%. The business had revenue of $86.51 million during the quarter, compared to analysts’ expectations of $86.80 million. On average, research analysts anticipate that Lantheus Holdings Inc will post 1.16 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was first reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/05/13/15410-shares-in-lantheus-holdings-inc-lnth-acquired-by-dupont-capital-management-corp.html.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

See Also: Stock Symbols Definition, Examples, Lookup

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings Inc (NASDAQ:LNTH).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.